 Connection
Charles Dinarello to Treatment Outcome
This is a "connection" page, showing publications Charles Dinarello has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.347 |
|
|
|
-
Dinarello CA, Joosten LA. Inflammation in rheumatology in 2015: New tools to tackle inflammatory arthritis. Nat Rev Rheumatol. 2016 Feb; 12(2):78-80.
Score: 0.050
-
Abbate A, Van Tassell BW, Christopher S, Abouzaki NA, Sonnino C, Oddi C, Carbone S, Melchior RD, Gambill ML, Roberts CS, Kontos MC, Peberdy MA, Toldo S, Vetrovec GW, Biondi-Zoccai G, Dinarello CA. Effects of Prolastin C (Plasma-Derived Alpha-1 Antitrypsin) on the acute inflammatory response in patients with ST-segment elevation myocardial infarction (from the VCU-alpha 1-RT pilot study). Am J Cardiol. 2015 Jan 01; 115(1):8-12.
Score: 0.046
-
Vojinovic J, Damjanov N, D'Urzo C, Furlan A, Susic G, Pasic S, Iagaru N, Stefan M, Dinarello CA. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2011 May; 63(5):1452-8.
Score: 0.036
-
Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005 Jun; 52(6):1794-803.
Score: 0.024
-
Kanni T, Argyropoulou M, Dinarello CA, Simard J, Giamarellos-Bourboulis EJ. MABp1 targeting interleukin-1a in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period. Clin Exp Dermatol. 2021 Jan; 46(1):162-163.
Score: 0.017
-
Cavalli G, Tomelleri A, De Luca G, Campochiaro C, Dinarello CA, Baldissera E, Dagna L. Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. Arthritis Res Ther. 2019 02 13; 21(1):54.
Score: 0.015
-
Voronov E, Dinarello CA, Apte RN. Interleukin-1a as an intracellular alarmin in cancer biology. Semin Immunol. 2018 08; 38:3-14.
Score: 0.015
-
De Luca G, Campochiaro C, Dinarello CA, Dagna L, Cavalli G. Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. Ann Intern Med. 2018 12 04; 169(11):819-820.
Score: 0.015
-
Marcondes AM, Hockenbery D, Lesnikova M, Dinarello CA, Woolfrey A, Gernsheimer T, Loghman-Adham M, Gelmont D, Storer B, Hansen JA, Deeg HJ. Response of Steroid-Refractory Acute GVHD to a1-Antitrypsin. Biol Blood Marrow Transplant. 2016 09; 22(9):1596-1601.
Score: 0.013
-
Tzanetakou V, Kanni T, Giatrakou S, Katoulis A, Papadavid E, Netea MG, Dinarello CA, van der Meer JWM, Rigopoulos D, Giamarellos-Bourboulis EJ. Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial. JAMA Dermatol. 2016 Jan; 152(1):52-59.
Score: 0.012
-
Roerink ME, Knoop H, Bredie SJ, Heijnen M, Joosten LA, Netea MG, Dinarello CA, van der Meer JW. Cytokine inhibition in chronic fatigue syndrome patients: study protocol for a randomized controlled trial. Trials. 2015 Oct 05; 16:439.
Score: 0.012
-
H?gh K?lb?k Kj?r AS, Brinkmann CR, Dinarello CA, Olesen R, ?stergaard L, S?gaard OS, Tolstrup M, Rasmussen TA. The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients. AIDS. 2015 Jun 19; 29(10):1195-200.
Score: 0.012
-
Abbate A, Kontos MC, Abouzaki NA, Melchior RD, Thomas C, Van Tassell BW, Oddi C, Carbone S, Trankle CR, Roberts CS, Mueller GH, Gambill ML, Christopher S, Markley R, Vetrovec GW, Dinarello CA, Biondi-Zoccai G. Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am J Cardiol. 2015 Feb 01; 115(3):288-92.
Score: 0.011
-
Gottlieb PA, Alkanani AK, Michels AW, Lewis EC, Shapiro L, Dinarello CA, Zipris D. a1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1? responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes. J Clin Endocrinol Metab. 2014 Aug; 99(8):E1418-26.
Score: 0.011
-
Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, Simonini G, Borsari G, Caso F, Lucherini OM, Frediani B, Bertoldi I, Punzi L, Galeazzi M, Cimaz R. Anakinra treatment in drug-resistant Behcet's disease: a case series. Clin Rheumatol. 2015 Jul; 34(7):1293-301.
Score: 0.011
-
Van Tassell BW, Arena R, Biondi-Zoccai G, Canada JM, Oddi C, Abouzaki NA, Jahangiri A, Falcao RA, Kontos MC, Shah KB, Voelkel NF, Dinarello CA, Abbate A. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol. 2014 Jan 15; 113(2):321-327.
Score: 0.011
-
Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, Oddi C, Roberts CS, Melchior RD, Mueller GH, Abouzaki NA, Rengel LR, Varma A, Gambill ML, Falcao RA, Voelkel NF, Dinarello CA, Vetrovec GW. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013 May 15; 111(10):1394-400.
Score: 0.010
-
G?l A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, Scannon P, Solinger A. Interleukin-1?-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis. 2012 Apr; 71(4):563-6.
Score: 0.009
-
Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R, Roach LM, Arena RA, Roberts CS, Varma A, Gelwix CC, Salloum FN, Hastillo A, Dinarello CA, Vetrovec GW. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol. 2010 May 15; 105(10):1371-1377.e1.
Score: 0.008
-
Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, Walter MR, Nagabhushan TL, Trotta PP, Pestka S. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 1998 Jun 15; 58(12):2489-99.
Score: 0.004
-
Kondo S, Pastore S, Fujisawa H, Shivji GM, McKenzie RC, Dinarello CA, Sauder DN. Interleukin-1 receptor antagonist suppresses contact hypersensitivity. J Invest Dermatol. 1995 Sep; 105(3):334-8.
Score: 0.003
-
Ho JL, Badar? R, Schwartz A, Dinarello CA, Gelfand JA, Sobel J, Barral A, Netto MB, Carvalho EM, Reed SG, et al. Diminished in vitro production of interleukin-1 and tumor necrosis factor-alpha during acute visceral leishmaniasis and recovery after therapy. J Infect Dis. 1992 Jun; 165(6):1094-102.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|